Drug repositioning: current scenario and future prospective for rewriting saga of drug development

Alok Dixit; Ajit K. Mishra; Chandra Veer Singh; Vinay Kumar Gupta; Devesh Pandey

doi:10.18203/2320-6012.ijrms20240867

Authors

Alok Dixit Department of Pharmacology, UPUMS, Saifai, Uttar Pradesh, India
Ajit K. Mishra Department of Pharmacology, UPUMS, Saifai, Uttar Pradesh, India
Chandra Veer Singh Department of Pharmacology, UPUMS, Saifai, Uttar Pradesh, India
Vinay Kumar Gupta Department of Pharmacology, UPUMS, Saifai, Uttar Pradesh, India
Devesh Pandey Department of Pharmacology, UPUMS, Saifai, Uttar Pradesh, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20240867

Keywords:

Drug development, Drug repurposing, Drug repositioning

Abstract

Drug development is a process that demands huge investment of resources and time with only 1 drug candidate successful in reaching market among 10,000 screened taking time duration of 10-15 years and millions of dollars. This high attrition rates discourage investors and researchers. The pharmaceutical industry is shifting its attention away from de novo drug research and towards discovering novel targets and indications for already-approved drugs. In order to accelerate the drug development process with reduced risk of failure and relatively lower costs, pharmaceutical companies have adopted drug repositioning as an alternative. Therefore, a good strategy for drug development would be drug repositioning or drug repurposing, which is to identify, investigate, and exploit new therapeutic uses of already-available, on-market drugs, as well as those that have been withdrawn due to toxicities or that remain on shelves in various stages of development. The outbreak of SARS-COV-19 shows that humanity is constantly vulnerable to epidemics and new microbial attacks and that there is no time to create disease-specific therapies. Consequently, it would seem advantageous to use what is already accessible. Novel therapeutic indications that have previously been approved by the market can reduce investment costs significantly in terms of money, resources, and most importantly, time, as long as they meet PKPD and toxicity standards. Sponsors and pharmaceutical corporations get enthusiastic about additional investments and initiatives related to drug development as a consequence. The upcoming therapeutic revolution, especially with the aid of artificial intelligence, is indicated by the successful applications of several already-available drugs against COVID-19 and the various phases of repurposed drugs against TB, colorectal cancer, Alzheimer’s disease, cervical cancer, and Parkinsonism.

Metrics

Metrics Loading ...

References

Medhi B, Prakash A. Text book of Advanced Pharmacology. Pharma Med. 2019:965-77.

Wilson JF. Alterations in processes and priorities needed for new drug development. Ann Intern Med. 2006;145(10):793-6.

Dueñas-González A, García-López P, Herrera LA, Medina-Franco JL, González-Fierro A, Candelaria M. The prince and the pauper. A tale of anticancer targeted agents. Mol Cancer. 2008:7:82.

Kunz E. Henri Laborit and the inhibition of action. Dialog Clin Neurosci. 2014;16(1):113.

Graul Al, Sobera L, Pina P, Tell M, Cruces E, Rosa E, et al. The year’s new drugs and biologics-2009. Drug News Perspect. 2010;23(1):7-36.

Kaitin KI. Deconstructing the drug development process: the new face of innovation. Clin Pharmacol Ther. 2010;87(3):356-61.

Schlander M, Hernandez-Villafuerte K, Cheng CY, Mestre-Ferrandiz J, Baumann M. How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment. Pharmacoeconomics. 2021;39(11):1243-69.

Tobinick EL. The value of drug repositioning in the current pharmaceutical market. Drug News Perspect. 2009;22(2):119-25.

DiMasi JA, Feldman L, Seckler A, Wilson A. Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Therapeut. 2010;87(3):272-7.

DiMasi JA, Grabowski HG. The cost of biopharmaceutical R&D: is biotech different? Manag Decis Econom. 2007;28(4‐5):469-79.

Nwaka S, Ridley RG. Virtual drug discovery and development for neglected diseases through public–private partnerships. Nature Rev Drug Discover. 2003;2(11):919-28.

Osborne KL, Davis SM. Duloxetine in the treatment of stress urinary incontinence. J Pharm Technol. 2005;21(6):337-40.

Tartaglia LA. Complementary new approaches enable repositioning of failed drug candidates. Expert Opin Investig Drugs. 2006;15(11):1295-8.

Sleigh SH, Barton CL. Repurposing strategies for therapeutics. Pharm Med. 2010;24:151-9.

Cichonska A, Rousu J, Aittokallio T. Identification of drug candidates and repurposing opportunities through compound–target interaction networks. Expert Opin Drug Discov. 2015;10(12):1333-45.

Stephen R, Knopf K, Reynolds MW, Luo W, Fraeman K. Pcn112 off-label use of oncology drugs in a community oncology emr database. Value Health. 2009;12(3):57.

Jin G, Fu C, Zhao H, Cui K, Chang J, Wong ST. A novel method of transcriptional response analysis to facilitate drug repositioning for cancer therapy. Cancer Res. 2012;72(1):33-44.

Blatt J, Corey SJ. Drug repurposing in pediatrics and pediatric hematology oncology. Drug Discov Today. 2013;18(1-2):4-10.

Houghton PJ, Morton CL, Gorlick R, Lock RB, Carol H, Reynolds CP, et al. Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program. Mol Cancer Ther. 2010;9(1):101-12..

Heinrich MC, Joensuu H, Demetri GD, Corless CL, Apperley J, Fletcher JA, et al. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res. 2008;14(9):2717-25.

Jin F, Zhao C, Chang W. A novel method of transcriptional response analysis to facilitate drug repositioning for cancer therapy. Cancer Res. 2012;72(1):33-44.

Quianzon CC, Cheikh IE. History of current non-insulin medications for diabetes mellitus. J Community Hosp Intern Med Perspect. 2012;2(3).

Levine R. Sulfonylureas: background and development of the field. Diabetes Care. 1984;7(1):3-7.

Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004;3(8):673-83.

Langedijk J, Mantel-Teeuwisse AK, Slijkerman DS, Schutjens MH. Drug repositioning and repurposing: terminology and definitions in literature. Drug Discov Today. 2015;20(8):1027-34.

Jourdan JP, Bureau R, Rochais C, Dallemagne P. Drug repositioning: a brief overview. J Pharm Pharmacol. 2020;72(9):1145-51.

Moncada S. Adventures in vascular biology: a tale of two mediators. Philos Trans R Soc Lond B Biol Sci. 2006;361(1469):735-59.

Jafari RM, Sheibani M, Nezamoleslami S, Shayesteh S, Jand Y, Dehpour AR. Drug repositioning: A review. J Iran Med Counc. 2018;1(1):7-10.

Miner J, Hoffhines A. The discovery of aspirin’s antithrombotic effects. Texas Hear Inst J. 2007;34(2):179-86.

Borel JF, Kis ZL. The discovery and development of cyclosporine (Sandimmune). Transplant Proc. 1991;23(2): 1867-74.

Shorter E. The history of lithium therapy. Bipolar Disord. 2009;11(2):4-9.

Harrison C. Coronavirus puts drug repurposing on the fast track. Nature Biotechnol. 2020;38(4):379-81.

Sleigh SH, Barton CL. Repurposing strategies for therapeutics. Pharmaceut Med. 2010;24(3):151-9.

Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020;19(3):149-50.

Chakraborty C, Sharma AR, Bhattacharya M, Agoramoorthy G, Lee SS. The Drug Repurposing for COVID-19 Clinical Trials Provide Very Effective Therapeutic Combinations: Lessons Learned From Major Clinical Studies. Front Pharmacol. 2021;12:1-15.

Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;323(18):1824-36.

Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today’s diseases? Lancet Infect Dis. 2003;3(11):722-7.

Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56(1):105949.

Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020;382:2327-36.

Chan KS, Lai ST, Chu CM, Tsui E, Tam CY, Wong MML, et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched COHORT study. Hong Kong Med J. 2003;9(6):399-406.

Arabi YM, Shalhoub S, Mandourah Y, Al-Hameed F, Al-Omari A, Qasim EA, et al. Ribavirin and interferon therapy for critically ill patients with Middle East respiratory syndrome: a multicenter observational study. Clin Infect Dis. 2020;70(9):1837-44.

Meini S, Pagotto A, Longo B, Vendramin I, Pecori D, Tascini C. Role of lopinavir/ritonavir in the treatment of covid-19: A review of current evidence, guideline recommendations, and perspectives. J Clin Med. 2020;9(7):1-15.

Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020:178:104787.

Chen C, Zhang Y, Huang J, Yin P, Cheng Z, Wu J, et al. Favipiravir versus Arbidol for COVID-19: a randomised clinical trial. Front Pharmacol. 2021:12:683296.

U.S Food and Drug Administration. FDA approves first treatment for COVID-19. 2020, 2020. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19. Accessed on 25 January 2024.

Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering. 2020;6(10):1192-8.

Low ZY, Farouk IA, Lal SK. Drug repositioning: New approaches and future prospects for life- debilitating diseases and the COVID-19 pandemic outbreak. Viruses. 2020;12(9):1058..

Fragoulis GE, McInnes IB, Siebert S. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatology (Oxford). 2019;58(1):43-54.

Kabinger F, Stiller C, Schmitzová J, Dienemann C, Kokic G, Hillen HS, et al. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat Struct Mol Biol. 2021;28(9):740-6.

Bernal JA, Silva GMM, Musungaie DB, Kovalchuk E, Gonzalez A, Reyes V, et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med. 2022;386(6):509-20.

Napolitano F, Zhao Y, Moreira V, Tagliaferri R, Kere J, D’Amato M, et al. Drug repositioning: A machine-learning approach through data integration. J Cheminform. 2013;5(1):30.

Xu K, Cote T. Database identifies FDA-approved drugs with potential to be repurposed for treatment of orphan diseases. Brief Bioinform. 2011;12:341-5.

Singh D, Singh A, Chawla PA. An overview of current strategies and future prospects in drug repurposing in tuberculosis. Explor Med. 2023;4(1):71-84.

Fatemi N, Karimpour M, Bahrami H, Zali MR, Chaleshi V, Riccio A, et al. Current trends and future prospects of drug repositioning in gastrointestinal oncology. Front Pharmacol. 2024:14:1329244.

Capistrano IR, Paul S, Boere I, Pantziarka P, Chopra S, Nout RA, et al. Drug repurposing as a potential source of innovative therapies in cervical cancer. Int J Gynecol Cancer. 2022;32(11):1377-86.

Davis MA, Delaney JR, Patel CB, Storgard R, Stupack DG. Nelfinavir is effective against human cervical cancer cells in vivo: a potential treatment modality in resource-limited settings. Drug Des Devel Ther. 2016;10:1837-46.